234 related articles for article (PubMed ID: 30638095)
1. Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study.
Farawela HM; Zawam HM; Al-Wakeel HA; El-Nagdy MH; El-Refaey FA; Abdel-Rahman HA
Scand J Clin Lab Invest; 2019; 79(1-2):65-70. PubMed ID: 30638095
[TBL] [Abstract][Full Text] [Related]
2. [Expression of SALL4 gene in patients with acute and chronic myeloid leukemia].
Chen Q; Qian J; Lin J; Yang J; Li Y; Wang CZ; Chai HY; Chen XX; Qian Z; Ma JC; Zhang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):315-9. PubMed ID: 23628023
[TBL] [Abstract][Full Text] [Related]
3. BMI1 gene expression in myeloid leukemias and its impact on prognosis.
Saudy NS; Fawzy IM; Azmy E; Goda EF; Eneen A; Abdul Salam EM
Blood Cells Mol Dis; 2014 Dec; 53(4):194-8. PubMed ID: 25084695
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
5. The differential expression pattern of the BMI-1, SALL4 and ABCA3 genes in myeloid leukemia.
Shen Q; Liu S; Hu J; Chen S; Yang L; Li B; Wu X; Ma Y; Yang J; Ma Y; Li Y
Cancer Cell Int; 2012 Oct; 12(1):42. PubMed ID: 23067006
[TBL] [Abstract][Full Text] [Related]
6. SALL4 Gene Expression in Acute Myeloid Leukemia.
Ibraheem FM; Badawy R; Ayoub MA; Hassan NM; Mostafa MN
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3121-3127. PubMed ID: 31653163
[TBL] [Abstract][Full Text] [Related]
7. The Study of SALL4 Gene and BMI-1 Gene Expression in Acute Myeloid Leukemia Patients.
Swelem RS; Elneely DA; Shehata AAR
Lab Med; 2020 May; 51(3):265-270. PubMed ID: 31552409
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
Mäkelä E; Pavic K; Varila T; Salmenniemi U; Löyttyniemi E; Nagelli SG; Ammunét T; Kähäri VM; Clark RE; Elo LL; Bachanaboyina VK; Lucas CM; Itälä-Remes M; Westermarck J
Clin Cancer Res; 2021 May; 27(10):2848-2860. PubMed ID: 33674272
[TBL] [Abstract][Full Text] [Related]
9. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
[TBL] [Abstract][Full Text] [Related]
10. Aberrant hypomethylation of SALL4 gene is associated with intermediate and poor karyotypes in acute myeloid leukemia.
Ma JC; Qian J; Lin J; Qian W; Yang J; Wang CZ; Chai HY; Li Y; Chen Q; Qian Z
Clin Biochem; 2013 Mar; 46(4-5):304-7. PubMed ID: 23201546
[TBL] [Abstract][Full Text] [Related]
11. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
12. A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis.
Li A; Yang Y; Gao C; Lu J; Jeong HW; Liu BH; Tang P; Yao X; Neuberg D; Huang G; Tenen DG; Chai L
J Clin Invest; 2013 Oct; 123(10):4195-207. PubMed ID: 24051379
[TBL] [Abstract][Full Text] [Related]
13. Translocation (2;3)(p13;q26) in two cases of myeloid malignancies. Acute myeloblastic leukemia (M2) and blastic phase of chronic myeloid leukemia.
Fleischman EW; Volkova MA; Frenkel MA; Konstantinova LN; Kulagina OE; Baranov AE; Gordeeva AA
Cancer Genet Cytogenet; 1996 Apr; 87(2):182-4. PubMed ID: 8625269
[TBL] [Abstract][Full Text] [Related]
14. Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia.
Fattizzo B; Radice T; Cattaneo D; Pomati M; Barcellini W; Iurlo A
Clin Lab; 2014; 60(11):1929-32. PubMed ID: 25648037
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
16. Molecular detection of survivin expression, antiapoptotic gene, and other prognostic markers, how they are correlated and how it could be of prognostic value in chronic myeloid leukemia patient.
Zhara M; Mourad H; Farouk G; Elbatch M; Ezzat S; Sami W
Egypt J Immunol; 2007; 14(2):51-62. PubMed ID: 20306657
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
[TBL] [Abstract][Full Text] [Related]
18. Loss of TG-Interacting Factor 1 decreases survival in mouse models of myeloid leukaemia.
Yan L; Davé UP; Engel M; Brandt SJ; Hamid R
J Cell Mol Med; 2020 Nov; 24(22):13472-13480. PubMed ID: 33058427
[TBL] [Abstract][Full Text] [Related]
19. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
20. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.
Heuser M; Beutel G; Krauter J; Döhner K; von Neuhoff N; Schlegelberger B; Ganser A
Blood; 2006 Dec; 108(12):3898-905. PubMed ID: 16912223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
